Clinical Trial Update: A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

This is a completed Phase 1/2 clinical trial evaluating IPI-926 in combination with gemcitabine for metastatic pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• IPI-926 (IPI-926)

Snippet

Sponsor: Infinity Pharmaceuticals, Inc. | Conditions: Metastatic Pancreatic Cancer | Phase 1, Phase 2 | Status: COMPLETED